Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

1/28/25 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GILD alert in real time by email

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2024 financial results and provide a business update.

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250128013206/en/

Jacquie Ross, CFA – Investors

[email protected]

Get the next $GILD alert in real time by email

Recent Analyst Ratings for

$GILD

Date	Price Target	Rating	Analyst
4/22/2025	$125.00	Overweight	Cantor Fitzgerald
3/4/2025	$115.00 → $132.00	Outperform	Oppenheimer
2/18/2025	$120.00	Hold → Buy	Deutsche Bank
2/13/2025	$108.00	Hold → Buy	DZ Bank
1/10/2025	$87.00 → $113.00	Equal-Weight → Overweight	Morgan Stanley
12/10/2024	$109.00	Buy	BofA Securities
11/15/2024	$110.00	Outperform	Wolfe Research
11/14/2024	$125.00	Buy	Citigroup

More analyst ratings

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Chat with this insight

Recent Analyst Ratings for
$GILD

$GILD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Dickinson Andrew D sold $275,425 worth of shares (2,500 units at $110.17), decreasing direct ownership by 1% to 165,110 units (SEC Form 4)

Chief Commercial Officer Mercier Johanna sold $330,510 worth of shares (3,000 units at $110.17), decreasing direct ownership by 2% to 120,168 units (SEC Form 4)

Interim Corp Controller & CAO Wilfong Diane E. converted options into 920 shares and covered exercise/tax liability with 340 shares, increasing direct ownership by 1% to 45,676 units (SEC Form 4)

$GILD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

$GILD
SEC Filings

SEC Form 13F-HR filed by Gilead Sciences Inc.

Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Gilead Sciences Inc.

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Chat with this insight

Recent Analyst Ratings for $GILD

$GILD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Dickinson Andrew D sold $275,425 worth of shares (2,500 units at $110.17), decreasing direct ownership by 1% to 165,110 units (SEC Form 4)

Chief Commercial Officer Mercier Johanna sold $330,510 worth of shares (3,000 units at $110.17), decreasing direct ownership by 2% to 120,168 units (SEC Form 4)

Interim Corp Controller & CAO Wilfong Diane E. converted options into 920 shares and covered exercise/tax liability with 340 shares, increasing direct ownership by 1% to 45,676 units (SEC Form 4)

$GILD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

$GILD SEC Filings

SEC Form 13F-HR filed by Gilead Sciences Inc.

Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Gilead Sciences Inc.

Recent Analyst Ratings for
$GILD

$GILD
Insider Trading

$GILD
Insider Purchases

$GILD
SEC Filings